Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.50 |
| ▸ | CDC25B | P30305 | 4/20 | 0.50 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.50 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 1/20 | 0.50 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.50 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.50 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | RECQL | P46063 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8366528 | 0.79 | IDO1 (0.34) | IDO1CDC25BPIN1EHMT2MAOA | |
| SCHEMBL1149272 | 0.71 | — | — | |
| SCHEMBL3673942 | 0.69 | CDC25B (0.41) | IDO1CDC25BPIN1EHMT2MAOA | |
| Naphthoquinone SCHEMBL8861335 | 0.68 | IDO1 (1.00) | IDO1CDC25BPIN1EHMT2MAOA | |
| Naphthoquinone SCHEMBL29354680 | 0.68 | IDO1 (1.00) | IDO1CDC25BPIN1EHMT2MAOA | |
| Naphthoquinone SCHEMBL11359780 | 0.68 | IDO1 (1.00) | IDO1CDC25BPIN1EHMT2MAOA | |
| Naphthoquinone SCHEMBL42139 | 0.68 | IDO1 (1.00) | IDO1CDC25BPIN1EHMT2MAOA | |
| SCHEMBL5497320 | 0.67 | IDO1 (0.38) | IDO1CDC25BPIN1EHMT2MAOA | |
| SCHEMBL9366483 | 0.67 | MEN1 (0.46) | IDO1CDC25BPIN1EHMT2MAOA | |
| Naphthoquinone SCHEMBL722080 | 0.66 | IDO1 (0.93) | IDO1CDC25BPIN1EHMT2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584745-B2 | Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2023-02-21 | — | — | US | claimed |
| US-20210032242-A1 | AROMATIC HETEROCYCLIC SUBSTITUTED OLEFIN COMPOUND, PREPARATION METHOD FOR SAME, PHARMACEUTICAL COMPOSITION OF SAME, AND APPLICATIONS THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2021-02-04 | — | — | US | claimed |
| US-20210032241-A1 | AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2021-02-04 | — | — | US | claimed |
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| WO-2024129931-A1 | ALPHA-V BETA-6(ανβ6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | disclosed |
| US-20240197700-A1 | Methods and Compositions for Treating Lysosomal Storage Disorders | HEALTH, SANFORD | 2024-06-20 | — | — | US | disclosed |
| US-20240182503-A1 | MACROCYCLE COMPLEMENT FACTOR B INHIBITORS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240174684-A1 | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS | BELLBROOK LABS, LLC | 2024-05-30 | — | — | US | disclosed |
| EP-4370113-A1 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | Avanti Biosciences Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240148716-A1 | COMPOSITIONS AND METHODS FOR ADJUVANT CANCER THERAPEUTICS | DUKE UNIVERSITY (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | disclosed |
| WO-2012031298-A2 | ETHYNYLBENZENE DERIVATIVES | DUKE UNIVERSITY (US) | 2012-03-08 | — | — | WO | disclosed |
| WO-2011100438-A2 | MOLECULAR THERMOELECTRIC DEVICE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2011-08-18 | — | — | WO | disclosed |
| US-20110136796-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2011056652-A1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054530-A1 | GPBP INHIBITION USING Q2 PEPTIDOMIMETICS | FIBROSTATIN, S.L. (ES) | 2011-05-12 | — | — | WO | disclosed |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | FIBROSTATIN, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| CN-1063180-C | 5H, 10H-imidazo [1, 2 -a] indeno [1, 2 -e] pyrazin-4-one derivatives, preparation thereof, and drugs containing said derivatives | RHONE POULENC RORER SA (FR) | 2001-03-14 | — | — | CN | disclosed |
| CN-1180357-A | 5H, 10H-imidazo [1, 2-a ] indeno [1, 2-e ] pyrazin-4-one derivatives, preparation thereof and medicaments containing same | RHONE POULENC RORER SA (FR) | 1998-04-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174684-A1 | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS | CGAS, STING1, IRF3 | IDO1 1932/4885CDC25B 1469/4885PIN1 4572/4885 |
| US-20210032242-A1 | AROMATIC HETEROCYCLIC SUBSTITUTED OLEFIN COMPOUND, PREPARATION METHOD FOR SAME, PHARMACEUTICAL COMPOSITION OF SAME, AND APPLICATIONS THEREOF | ALK, ALKBH5, ALKBH3 | IDO1 673/4885CDC25B 3924/4885PIN1 3034/4885 |
| US-20240150362-A1 | Substituted Pyrrolotriazines | USP7, UBA7, USP5 | IDO1 1453/4885CDC25B 1853/4885PIN1 326/4885 |
| US-20110105545-A1 | GPBP inhibition using Q2 peptidomimetics | HSP90B1, ERP44, HSPA5 | IDO1 4874/4885CDC25B 1827/4885PIN1 1252/4885 |
| US-20240182503-A1 | MACROCYCLE COMPLEMENT FACTOR B INHIBITORS | CFB, CFH, C9 | IDO1 4794/4885CDC25B 1244/4885PIN1 4046/4885 |
| US-20210032241-A1 | AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ALK, NOTUM, WEE1 | IDO1 833/4885CDC25B 4573/4885PIN1 1426/4885 |
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | SREBF2, SREBF1, SLC2A2 | IDO1 4734/4885CDC25B 4442/4885PIN1 4456/4885 |
| US-20110136796-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885CDC25B 153/4885PIN1 493/4885 |
| US-11584745-B2 | Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof | ALK, NOTUM, WEE1 | IDO1 833/4885CDC25B 4573/4885PIN1 1426/4885 |
| US-20240197700-A1 | Methods and Compositions for Treating Lysosomal Storage Disorders | GAA, GBA1, MAN2B1 | IDO1 4737/4885CDC25B 4438/4885PIN1 4764/4885 |
| US-20240148716-A1 | COMPOSITIONS AND METHODS FOR ADJUVANT CANCER THERAPEUTICS | TP53, PLK1, NRAS | IDO1 2938/4885CDC25B 462/4885PIN1 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.